PubMed · 2008 · 34 citations · 22 references
MedicineInfectious DiseasesMicrobiologyAntimicrobial PharmacologyAntimicrobial PharmacotherapyMedical MicrobiologyAnthelmintic PharmacologyAntifungal AgentsAntifungal PharmacologyAntiparasitic ChemotherapyAntiparasitic PharmacologyProtozoal InfectionsAntileishmanial ChemotherapyAntileishmanial TreatmentChemotherapy Of Protozoan InfectionsLeishmania Species ComplexLeishmaniasis PathogenesisMacrophage Responses To LeishmaniaPhagocytic ActivityTreatment Of Leishmaniasis
Azithromycin, an azalide antibiotic, is highly concentrated within different phagocytic cells, especially macrophages. The potential antileishmanial activity of azithromycin against three species of Leishmania from the New World was assessed using in vitro models. Azithromycin decreased viability of promastigote cultures of Leishmania (Leishmania) amazonensis, Leishmania (Viannia) braziliensis, and Leishmania (Leishmania) chagasi as determined by the colorimetric Alamar blue assay. In amastigote intracellular cultures, a significant decrease in infected macrophages counts was observed for all three species with IC(50) of 20.83 (27 micromol/L), 2.18 (2.7 micromol/L), and 6.12 (7.8 micromol/L) microg/mL, respectively. Azithromycin showed in vitro activity against L. (L.) amazonensis, L. (V.) braziliensis, and L. (L.) chagasi and may offer an alternative to current leishmaniasis treatment.
22
Ronald P. Gladue, G. Michael Bright, Richard E. Isaacson et al. · Antimicrobial Agents and Chemotherapy · 1989 · 476 citations
Medicine, Immunology, Pharmacology +14
Current scenario of drug development for leishmaniasis.
Simon L. Croft, Karin Seifert, Vanessa Yardley · PubMed · 2006 · 392 citations · Full text